Edward R. S.

Imcyse is a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases. The company’s unique technology platform can address a wide range of autoimmune and immunologic diseases. Imotopes™ are modified synthetic peptides, which specifically block improper immune activity. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no effective therapeutic alternative and has the potential to cure patients without impairing their immune defenses. Our vision is to become a leader in the field of active specific immunotherapy and to prevent, stop and potentially cure autoimmune diseases. Headquartered in Liège, Belgium, Imcyse was founded as a spin-off of the Catholic University of Leuven (KULeuven). Imcyse’s Imotope™ technology platform is protected by a robust, international intellectual property portfolio. Our lead Imotope™, IMCY-0098, is in phase 2 clinical testing for early onset type 1 diabetes.

We build innovative, high capacity wireless IP networks using our 100% in-house developed products for the offshore market. Every year an increasing number of offshore operations take place in harsh, remote areas with multiple vessels involved. By connecting people, processes and places we strive to maximize profitability and make better, safer decisions faster. Our products allow our clients to easily exchange video, synchronize large files and enable machine to machine communication onshore and offshore.

TRAINM is an outpatient neuro rehabilitation clinic group, with locations in Antwerp and Ghent-South, treating children and adults with a broad range of neurological disorders such as cerebral palsy, stroke, acquired brain injury, MS, Parkinson's, spinal cord injury and disorders of consciousness. TRAINM maximizes patient recoveries by offering medical rehab therapies by a multidisciplinary team of medical doctors, neuro physical therapists, functional therapists, neuropsychologists and speech therapists. TRAINM offers its patients personalized medical rehab therapies using the latest scientifically proven technologies, such as non-invasive brain stimulation, virtual reality, neurogaming and robotics. For more information, please visit our website www.trainm.com

Irisium provides insightful analytics and contextual surveillance to exchanges, regulators, buy and sell side firms. This enables market participants to meet their regulatory and compliance obligations with confidence. The Irisium solution has been developed by a team of regulatory and market experts, underpinned by great technology. This means that firms can meet their surveillance obligations with confidence, gaining insightful business intelligence with ease. Irisium is owned by KRM22 and Cinnober Financial Technology. For more information visit www.Irisium.com

“Talents and technologies for an optimized and sustainable workplace.” AREMIS is a leading consulting, technology and services company dedicated to Corporate Real Estate and Facility Management. As a Human Resources Developer and Provider, AREMIS selects, develops and insources expert profiles to complement the building, facilities and real estate organisation of its customers. As a Business Solutions Provider, AREMIS implements information systems and streamlines business processes to optimize real estate and occupancy costs and reduce the environmental footprint.

BRAIN-NM Clinics, with locations in Antwerp and Ghent-South, offers groundbreaking neuromodulation treatments that have been proven effective through scientific research. These treatments serve as compelling alternatives or supplements to conventional medications and psychotherapies. Our expert medical team consists of renowned and award-winning psychiatrists and neurologists who ensure the most up-to-date, evidence-based, and personalized treatments for a range of neuropsychiatric and other disorders, such as depression, PTSD, OCD, burnout, ADHD, nicotine addiction, migraine, concussion and chronic pain. BRAIN-NM Clinics leverages a state-of-the-art infrastructure and a team of accomplished academic professionals to facilitate a distinctive and translational approach that bridges the divide between pioneering neuroscience and clinical practice. This approach allows patients to benefit from access to recent evidence-based and advanced treatment protocols that may not be available elsewhere. For more information, contact us at info@brain-nm.com.

Imcyse is a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases. The company’s unique technology platform can address a wide range of autoimmune and immunologic diseases. Imotopes™ are modified synthetic peptides, which specifically block improper immune activity. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no effective therapeutic alternative and has the potential to cure patients without impairing their immune defenses. Our vision is to become a leader in the field of active specific immunotherapy and to prevent, stop and potentially cure autoimmune diseases. Headquartered in Liège, Belgium, Imcyse was founded as a spin-off of the Catholic University of Leuven (KULeuven). Imcyse’s Imotope™ technology platform is protected by a robust, international intellectual property portfolio. Our lead Imotope™, IMCY-0098, is in phase 2 clinical testing for early onset type 1 diabetes.

Were a Brussels-based start-up studio & incubator. We believe that digital solutions are the answer to a more sustainable, accessible, and better healthcare for everyone. Lets co-create!

We build innovative, high capacity wireless IP networks using our 100% in-house developed products for the offshore market. Every year an increasing number of offshore operations take place in harsh, remote areas with multiple vessels involved. By connecting people, processes and places we strive to maximize profitability and make better, safer decisions faster. Our products allow our clients to easily exchange video, synchronize large files and enable machine to machine communication onshore and offshore.